Large cell lymphoma

Anaplastic large-cell lymphoma, T or null cell, primary cutaneous type... 

Lymphomas not included in Working Formulation mycosis fungoides, mantle cell lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT), anaplastic large cell lymphoma, angiocentric lymphoma, angioimmunoblastic lymphadenopathy (AILD), Castleman s disease, adult T-cell leukemia/lymphoma. 

K. N. Konstantinov, B. A. Robbins, and F.-T. Liu, Galectin-3, a /l-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma, Am. J. Path., 148 (1996) 25-30. 

H8. Horst, E., Meijer, C., Radaszkiewicz, T., Ossekoppele, G., Van Krieken, J., and Pals, S. T., Adhesion molecules in the prognosis of diffuse large cell lymphoma expression of a lymphocyte homing receptor (CD44), LFA-1 (CDIIa/18) and ICAM-1 (CD54). Leukaemia 4, 595-599 (1990). 

Some lymphomas are unreactive with antibodies to CD45, such as lymphomas showing plasmacytoid differentiation or anaplastic large-cell lymphomas. 

MM = multiple myeloma ATL = adult T-cell leukemia ALL = acute lymphoblastic leukemia CLL = chronic lymphocytic leukemia FCC = follicular center cell lymphoma DLC = diffuse large cell lymphoma TRB = T-cell rich B-cell lymphoma ALCL = anaplastic large cell lymphoma MALT = mucosa-associated lymphoid tissue-type lymphoma LC = lung cancer CMM = cutaneous malignant melanoma TCC = transitional cell carcinoma CSCC = cutaneous squamous cell carcinoma. 

IL-14. IL-14 can be produced by aggressive intermediate (diffuse large cell) lymphomas of B cell-type non-Hodgkin s lymphoma (NHL-B) in patients with lymphomatous effusions. The autocrine or paracrine production of IL-14 may play a significant role in the rapid proliferation of aggressive NHL-B (F4). 

CLL/SLL, Chronic lymphocytic leukemia/small lymphocytic lymphoma MCL, mantle cell lymphoma FL, follicular lymphoma MZL/MALT, marginal zone lymphoma/mucosa-associated lymphoid tisuse lymphoma SMZL, splenic marginal zone lymphoma HCL, hairy cell leukemia DLCL, diffuse large-cell lymphoma PCM, plasma cell myeloma BCL-1, cyclin D1 FDC MW, Follicular dendritic cell meshworks CK, cytokeratin LELs, lymphoepitheilal lesions. 

Diffuse Large-Cell Lymphoma (DLCL). These clinically aggressive tumors may present in lymph nodes or in extranodal sites (Hll). They can occur in patients of all ages (Al, A14). Most cases arise de novo however, some may represent transformation from a low-grade lymphoma. 

Occasional DLCLs are CD5-positive. These cases may be either de novo CD5-positive large-cell lymphomas or represent cases that have transformed from either CLL/SLL or MCL the transformed MCL cases are BCL-l-immunopositive, whereas many of the transformed CLL/SLL cases are CD23-positive (B14, D26, K30, M13, Yl). CD5-positive de novo DLCL is a more aggressive disease process and is associated with decreased survival (H8, Yl). 

Anaplastic Large-Cell Lymphoma (ALCL). These tumors are composed of CD30-positive pleomorphic cells. There are several variants common (accounting for about 70% of cases), lymphohistiocytic (10%), small cell (< 10%), and giant cell (rare) (B11, F5, K10, S23). 

All. Anagnostopoulos, I., Herbst, H., Niedobitek, G., and Stein, H., Demonstration of monoclonal EBV genomes in Hodgkin s disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 74, 810-816 (1989). 

B9. Beljaards, R. C., Kaudewitz, P., Berti, E., Gianotti, R., Neumann, C., Rosso, R., Paulli, M., Meijer, C. J., and Willemze, R., Primary cutaneous CD30-positive large cell lymphoma Definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients. CancerlX, 2097—2104 (1993). 

B24. Brousset, P., Rochaix, P., Chittal, S., Rubie, H., Robert, A., and Delsol, G., High incidence of Epstein—Barr virus detection in Hodgkin s disease and absence of detection in anaplastic large-cell lymphoma in children. Histopathology 23, 189—191 (1993). 

C9. Cerroni, L., Rieger, E., Hodl, S., and Kerl, H., Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am. J. Surg. Pathol. 16, 543-552 (1992). 

C15. Chan, J. K. C., Anaplastic large cell lymphoma Redefining its morphologic spectrum and importance of recognition of the ALK-positive subset. Adv. Anat. Pathol. 5, 281-313 (1998). 

D9. Delsol, G., Ralfkiaer, E., Stein, H., Wright, D. H., and Jaffe, E. S., Anaplastic large cell lymphoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (E. S. Jaffe, N. L. Harris, H. Stein, and J. W. Vardiman, eds.), pp. 230-235. IARC Press, Lyon, (2001). 

F9. Felgar, R. E., Salhany, K. E., Macon, W. R., Pietra, G. G., and Kinney, M. C., The expression of TIA-1 + cytolytic-type granules and other cytolytic lymphocyte-associated in CD30+ anaplastic large cell lymphomas (ALCL) Correlation with morphology, immunophenotype, ultrastructure, and clinical features. Hum. Pathol. 30, 228—236 (1999). 

F13. Foss, H. D., Anagnostopoulos, I., Araujo, I., Assaf, C., Demel, G., Kummer, J. A., Hummel, M., and Stein, H., Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 88, 4005-4011 (1966). 

K3. Kaudewitz, P., Stein, H., Dallenbach, F., Eckert, F., Bieber, K., Burg, G., and Braun-Falco, O., Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical characteristics. Am. J. Pathol. 135, 359—367 (1989). 

K10. Kinney, M. C., and Kadin, M. E., The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Am. J. Clin. Pathol. Ill, S56—S67 (1999). 

K29. Krenacs, L., Wellmann, A., Sorbara, L., Himmelmann, A. W., Bagdi, E., Jaffe, E. S., and Raffeld, M., Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin s disease Evidence for distinct cellular origin. Blood 89, 980-989 (1997). 

K30. Kroft, S. H., Dawson, D. B., and McKenna, R. W., Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases. Am. J. Clin. Pathol. 115, 385-395 (2001). 

M14. Matolcsy, A., Inghirami, G., and Knowles, D. M., Molecular genetic demonstration of the diverse evolution of Richter s syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma). Blood 83, 1363—1372 (1994). 

N3. Nakamura, S., Shiota, M., Nakagawa, A., Yatabe, Y., Kojima, M., Motoori, T., Suzuki, R., Kagami, Y., Ogura, M., Morishima, Y., Mizoguchi, Y., Okamoto, M., Seto, M., Koshikawa, T., Mori, S., and Suchi, T., Anaplastic large cell lymphoma a distinct molecular pathologic entity A reappraisal with special reference to p80(NPM/ALK) expression. Am. J. Surg. Pathol. 21, 1420-1432 (1997). 

P4. Penny, R. J., Blaustein, J. C., Longtine, J. A., and Pinkus, G. S., Ki-l-positive large cell lymphomas, a heterogenous group of neoplasms. Morphologic, immunophenotypic, genotypic, and clinical features of 24 cases. Cancer 68, 362-373 (1991). 

P16. Pittaluga, S., Wiodarska, I., Pulford, K., Campo, E., Morris, S. W., Van den Berghe, H., and De Wolf-Peeters, C., The monoclonal antibody ALKI identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am. J. Pathol. 151,... 

Stein, H., Foss, H. D., Durkop, H., Marafioti, T., Delsol, G., Pulford, K., Piled, S., andFalini, B., CD30(+) anaplastic large cell lymphoma A review of its histopathologic, genetic, and clinical features. Blood 96, 3681-3695 (2000). 

J. J., Meijer, J. W., Willemze, R., Hilgers, J., and Meijer, C. J., MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J. Clin. Pathol. 54, 933-939 (2001). 

---